Anti glutamate-decarboxylase antibodies: A liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus by Szűcs, Anna et al.
Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzôi jog szabályozása alá esik.
Ideggyogy Sz 2014;67(7–8):269–271. 269
ESETISMERTETÉS
ANTI GLUTAMATE-DECARBOXYLASE ANTIBODIES: 
A LIAISON BETWEEN LOCALISATION RELATED EPILEPSY,
STIFF-PERSON SYNDROME AND 
TYPE-1 DIABETES MELLITUS  
Anna SZÛCS1, Gábor BARCS1, Gábor WINKLER2, Zsuzsanna SOÓS2, András FOLYOVICH2, 
Anna KELEMEN1, Péter VÁRALLYAY1, Anita KAMONDI1
1National Institute of Neuroscience, Budapest
2Szent János Hospital, Budapest
ANTI-GLUTAMÁT-DEKARBOXILÁZ ANTITESTEK: 
KAPCSOLAT A LOKALIZÁCIÓFÜGGÔ EPILEPSZIA, 
A STIFF-PERSON-SZINDRÓMA ÉS AZ 1-ES TÍPUSÚ 
DIABETES MELLITUS KÖZÖTT
Szûcs A, MD; Barcs G, MD; Winkler G, MD; Soós Zs, MD;
Folyovich A, MD; Kelemen A, MD; Várallyay P, MD; 
Kamondi A, MD
Ideggyogy Sz 2014;67(7–8):269–271.
Két stiff-person-szindrómás, a szérumban emelkedett glu-
tamát-dekarboxiláz-antitest (anti-GAD) -szintet hordozó
beteg esetét ismertetjük. Mindketten parciális epilepsziában
és 1-es típusú diabetes mellitusban, valamint további
autoimmun betegségekben is szenvedtek. 
Saját eseteink és az irodalom alapján arra következtetünk,
hogy emelkedett szérum-anti-GAD-szinttel járó stiff-person-
szindróma esetén további autoimmun betegségek, elsôsor-
ban 1-es típusú diabetes keresése indokolt. Másfelôl, a par-
ciális epilepszia társulása egyes, emelkedett
anti-GAD-szinttel járó kórképekkel arra utal, hogy az ilyen
esetekben anti-GAD-függô autoimmun patomechanizmus
állhat az epilepszia hátterében is.
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We present two patients with partial epilepsy, type-1 diabetes
and stiff person syndrome associated with high serum auto-
antibody levels to glutamate-decarboxylase (anti-GAD). Both
patients were or have suffered from additional autoimmune
conditions. 
The presence of stiff person syndrome and elevated anti-
GAD levels have to make clinicians look for additional
autoimmune conditions including type-1 diabetes. On the
other hand, the co-morbidity of partial epilepsy with autoim-
mune conditions in patients with elevated serum anti-GAD
suggests an autoimmune mechanism of partial epilepsy in
these cases. 
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Glutamate-decarboxylase (GAD) located withinthe nerve terminals of GABAergic neurons and
the beta-cells of the pancreas, is the rate-limiting
enzyme converting glutamate to gamma-hydroxy-
butyrate (GABA). Auto-antibodies to GAD (anti-
GAD) target the intracellular GAD presented to
autoimmune reaction by B lymphocytes and HLA
class II molecules1. Serum anti-GAD is detected in
80% of diabetes mellitus type-1 (DM1) patients2, 3 as
well as in late onset isolated cerebellar ataxia;
autoimmune poly-endocrine syndrome, cerebellar
ataxia with poly-endocrine autoimmunity; rheuma-
toid arthritis, myasthenia gravis, autoimmune
thyreoiditis; and certain para-neoplastic syndromes4. 
Significantly higher anti-GAD (IgG) levels with
different epitope specificity than in DM1 are pres-
ent in 60-80% of patients with stiff person’s syn-
drome (SPS); a rare condition (prevalence 1/
1 000 000) characterized by stiffness and cramps of
striated muscles, disturbing normal movement5, 6. 
The classical criteria of SPS are as follows7: 
– Stiffness, tightness in trunk and proximal limbs, 
– Prominent lumbar lordosis,
– Muscle cramps,
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– Parallel muscle activity of antagonistic muscles
simultaneously; in at least one axial muscle (the
EMG may be normal), 
– No brainstem-, basal ganglia-, or moto-neuron
signs; normal sensory, autonomic and cognitive
functions,
– Female preponderance,
– Association with other autoimmune diseases,
– Pulmonary/breast cancer in 15%.
Besides anti-GAD, additional auto-antibodies are
found in SPS8: tyrogastric antibodies, islet-cell anti-
bodies, auto antibodies against GABA-ergic neu-
rons, 125/130 kd protein, amphiphysin and ge -
phyrin, GABA A receptor-associated protein. 
Ten percent of SPS patients have epilepsy and
anti-GAD (IgG) was detected in seven out of 51
(13%) pharmaco-resistant partial epilepsy patients
against none of 49 with generalized epilepsy9. 
We present two female patients sharing SPS, par-
tial epilepsy and DM1; both suffering also in addi-
tional autoimmune conditions. We want to call
attention to this multi-organ co-morbidity and to
raise the possibility of anti-GAD related autoim-
mune aetiology in some epilepsies.
Case studies
PATIENT 1
A 51-year-old female had brain concussion at age
19. At age 29 complex partial and generalized
tonic-clonic seizures started with right temporal
interictal spikes seen on her EEG. Subcortical white
matter lesions were detected on the MRI brain-scan
of the patient; no hippocampal sclerosis was seen.
No seizure freedom could be reached by adequately
selected and therapeutic dose antiepileptic drugs. 
At age 39 DM1 was diagnosed. At age 45 sacro-
ileitis was diagnosed and sero-negative spondy-
larthritis was suspected. 
At age 46, stiffness in the lumbar spine and limb
muscles as well as painful cramps in the thigh
developed. Electromyography at age 49 showed
simultaneous motor activity in the antagonist mus-
cles of the thigh, which could be suspended by
intravenous diazepam. The diagnosis of SPS was
supported by high anti-GAD titre in her serum
[103.24 U/ml (reference <20)]. After unsuccessful
treatment with Pregabaline and improvement on
Diazepam; five sessions of plasma aphaeresis were
instituted resulting in significant improvement of
her stiffness. One month later she has become
seizure free for six months on unchanged antiepi -
leptic medication.
PATIENT 2
A 69-year-old female had partial epilepsy from age
20, treated with phenytoin and carbamazepine. She
had generalized tonic-clonic seizures and left tem-
poral lobe spikes on her EEG. After antiepileptic
treatment lasting for 15 years, she has become
seizure-free, so the antiepileptic medications could
be discontinued. Her DM-1 started at age 40. 
At age 58 stiff lower limbs and trunk developed
with hyper-lordotic posture and painful cramps in
leg-muscles. She was unable to bend and had opisto-
tonus when lying on her back. Minimal effort caused
tachycardia. The whole-spine MRI scan was normal,
the MRI brain-scan revealed cerebellar atrophy.
Electromyography (without parallel agonist-antago-
nist muscle testing) was normal, but there was typi-
cal clinical presentation for SPS: the small lady could
be pushed into the MRI-tube supported at her low
back only; not bending at all. Her serum anti-GAD
(IgG) was 5100U/ml (reference<20) supporting the
diagnosis of SPS. Treat ment with clonazepam and
baclofen decreased her muscle-stiffness, she was
unable to walk without them. Intravenous adminis-
tration of Methyl pred nisolon 1000 mg/day for a
week did not help. Her mobility worsened over the
years, her cerebellar ataxia also progressed till she
became wheelchair-bound. 
Because of her diarrhoea and weight loss, bowel
biopsy has been carried out; and positive anti-
gliadin antibodies were found in her serum, celiac
disease was diagnosed at age 64. 
Discussion
The diagnosis of SPS was supported by the clinical
presentation and high serum anti-GAD antibody
titres in both patients; no CSF testing was per-
formed. EMG evidence was present only in patient
1. The autoimmune mechanism of both SPS and
epilepsy of patient 1 is supported by her improve-
ment of muscle stiffness as well as becoming
seizure free; in response to plasma exchange thera-
py. The steroid treatment of patient 2 proved to be
insufficient. 
The apparently distant combination of SPS, DM1
and partial epilepsy was described by Solimena and
colleagues back in 198810 and was reported later11.
Although we haven’t performed full autoimmune
screening in our patients, their laboratory check-up
based on their specific syndrome revealed addition-
al autoimmune conditions e.g. sacro-ileitis (Patient
1); celiac disease and progressive cerebellar ataxia
(Patient 2). 
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Celiac disease shares the demographic features
of SPS. Serum antigliadin antibodies (diagnostic for
celiac disease) are found in 30-40% of sporadic
cerebellar ataxia patients12. Because celiac disease
may manifest as “gluten ataxia” and cause
seizures13; the epilepsy and cerebellar ataxia of
patient 2 could be related both to her celiac disease
and her high serum anti-GAD level.
Both SPS and epileptic seizures respond to
GABAergic agonists as benzodiazepines, sodium
valproate, baclofen and vigabatrin. There are
decreased cortical GABA levels in both condi-
tions14–16 as evidenced by MR spectroscopy, sug-
gesting an aetiological role of low GABA-related
cortical inhibition17– 19. 
It has been recently shown that GAD-67 is expres-
sed in hippocampal mossy fibers of temporal lobe
epilepsy patients20 offering a clue why partial epilep-
sy unlike generalized epilepsy is associated to GAD
autoimmunity; and intrathecal anti-GAD synthesis
has been found in 77% of pharmaco-resistant tempo-
ral lobe epilepsy patients with elevated serum anti-
GAD11. Low cortical GABA may be due to
decreased glutamate-GABA conversion; as a result
of anti-GAD autoimmunity. The beneficial effect of
corticosteroids, intravenous immu noglobulin and
plasma-aphaeresis in SPS support this hypothesis,
and the role of autoimmunity in epilepsy is support-
ed by the intra-thecal presence of anti-GAD antibod-
ies found in status epilepticus patients21. 
The combination of different autoimmune condi-
tions in our patients suggests that the diagnosis of
SPS and high anti-GAD level in the serum have to
make clinicians seek for co-morbid autoimmune
conditions and keep in mind the risk (up to 10%) of
the co-occurrence of epilepsy in these patients.
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